New Data on Vorasidenib & Low-Grade Glioma
- New data presented at a major brain tumor meeting in November 2026 suggest the targeted pill vorasidenib (Voranigo) may reduce seizures in people with a specific type of glioma that is classified as grade 2 and has an IDH mutation.
- There are two types of IDH-mutant glioma: oligodendroglioma and astrocytoma. Seizure control was more pronounced in patients with oligodendroglioma.
- Seizure control is critically important for this group of patients. “For patients with IDH mutant glioma, they represent the group that is more likely to have seizures,” Dr. Katherine Peters, a neuro-oncologist at Duke Cancer Center, tells SurvivorNet.
- Here, a panel of brain tumor experts discuss the new data on vorasidenib, how long the drug may take to work, and why some patients with hard to control seizures might still need radiation and chemotherapy.
At SNO, held in Philadelphia last weekend, SurvivorNet sat down with a panel of brain cancer experts to learn more about what the update means for glioma patients.
Read MoreWhy Do These Tumors Cause Seizures?
A glioma is a tumor that starts in the brain’s glial cells, which support and protect nerve cells. Currently, vorasidenib is approved for patients whose glioma is classified as “grade 2,” which tends to indicate slower growing disease.
Many of these tumors have a change, or mutation, in a gene called IDH (isocitrate dehydrogenase). This IDH mutation makes the tumor produce a chemical called 2-hydroxyglutarate, or 2-HG, which helps the tumor grow.
Dr. Peters says seizures are “a presenting symptom,” or the symptom that first suggests a glioma may be present, about a third of the time.
“During the disease trajectory it can be upwards to 85%,” she explains. “And for patients with IDH mutant glioma, they represent the group that is more likely to have seizures because of where these tumors are located in the brain, and also because their tumor produces a chemical called 2-Hydroxyglutarate, which promotes seizures.”
Vorasidenib’s Role in Glioma Treatment
Vorasidenib (brand name Voranigo) is a pill taken once a day. It blocks the faulty IDH proteins, so the tumor makes less 2-HG. It was tested in INDIGO, a phase 3 trial. The large, late-stage study compared vorasidenib with a placebo in people who’d had surgery but no radiation or chemotherapy.
The U.S. Food and Drug Administration (FDA) approved vorasidenib in August 2024 after the trial showed it held off tumor growth.
Dr. Iwamoto says the drug matters for people “that are usually young adults at the peak of their lives.” Because it’s well tolerated, he says, patients “can keep their normal lives going.”
Researchers shared a new look at INDIGO at this years SNO meeting, using data through January 17, 2025, that provided the encouraging update on seizure control.
They focused on patients who’d had at least one seizure, either before the trial or during it. In that group, people on vorasidenib had about 72% fewer seizures than people on placebo.
“This new INDIGO data show that for the patients that had at least one seizure during the clinical trial, there was better control of seizures on vorasidenib versus placebo,” Dr. Peters says. “It’s quite compelling.”
Understanding the Latest Trial Data
The type of glioma a patient had impacted how effective vorasidenib was. There are two main kinds of IDH-mutant glioma. Oligodendrogliomas have a specific genetic change, where pieces of chromosomes 1 and 19 are missing (doctors call it a 1p/19q codeletion). Astrocytomas, the other type, do not have this feature.
In people with oligodendroglioma, seizures dropped by about 91% compared with placebo. In people with astrocytoma, the difference was small and could have been due to chance.
“This drug can help seizures, but sometimes it takes time for it to kick in,” Dr. Patrick Wen, a neuro-oncologist at Mass General Brigham Cancer Institute, tells SurvivorNet. “And the benefit is much more for patients with oligodendrogliomas than astrocytomas.”
The researchers found that people with bigger tumors at the start of the trial tended to have more seizures. Seizures also became more common after a tumor started growing again.
That suggests vorasidenib may cut seizures mainly by keeping the tumor in check. It also helps explain why the effect isn’t fast.
Dr. Peters adds that “the time to response is not immediate on scans,” and it can take longer than a year on the drug to see meaningful response.
Vorasidenib’s Impact on Quality of Life
Researchers measured quality of life with the FACT-Br (Functional Assessment of Cancer Therapy–Brain), a questionnaire about how patients feel physically, emotionally, and about brain-related symptoms like memory problems.
Across the whole trial, there was no clear difference between the two groups. But among people who’d had seizures, those on vorasidenib went longer before their quality of life got noticeably worse. That result was borderline.
“If you can control seizures and symptoms better, you know, patients quality of life will be better,” Dr. Iwamoto says.
Dr. Wen adds that vorasidenib “is a very well tolerated drug, and the long-term toxicity follow up data doesn’t show any new problems.”
The most common serious side effect is a rise in liver enzymes, which shows up on blood tests. Patients taking the drug will need to have their liver checked regularly.
INDIGO’s Limitations
There were some limitations to the new trial data, since the research on seizures and quality of life was exploratory. Vorasidenib may not control or reduce seizures enough for all eligible patients.
“I think if patients have intractable seizures from onset and they’re not tolerating the seizure medicines, radiochemotherapy probably is still the way to go because that will likely achieve better control quicker,” Dr. Wen says.
Dr. Iwamoto sees room for both paths.
“I would still go patient by patient,” he says. “There are patients that… there are frequent seizures. But you may be able to control with anti-seizure medications and still consider vorasidenib as the first line.”
Some patients would rather avoid radiation and chemotherapy, at least for now. Dr. Peters says that can be a reasonable choice with careful watching.
“I don’t think it’s unreasonable to consider options like starting [vorasidenib] as long as you’re doing very close monitoring,” she says.
“I would always consider all the tools in my toolbox. And that’s what I tell my patients,” Dr. Peters adds. “We have all these different tools. And now we have… vorasidenib, something that’s added to that.”
Questions To Ask Your Doctor
- Is my tumor an oligodendroglioma or an astrocytoma?
- Has my tumor been tested for an IDH mutation?
- How is my glioma classified and what does that mean for treatment?
- Could vorasidenib help my seizures, or would radiation and chemotherapy work faster for me?
- Should I keep taking my current seizure medicine?
Learn more about SurvivorNet's rigorous medical review process.

